Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim
University of California, Davis
H. Lee Moffitt Cancer Center and Research Institute
Johannes Gutenberg University Mainz
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim